VasoRx is developing RNA therapies for diseases of the cardiovascular VasoRx is leading the translation of technologies discovered at Massachusetts Institute of Technology (M.I.T) and Yale for the delivery of RNAs for the treatment of diseases. With the world’s first approved RNAi therapeutic, the field of RNA medicines is rapidly expanding. VasoRx utilizes novel nanoparticles that are dramatically expanding the opportunities for developing RNA therapies for diseases of the cardiovascular system as well as oncology. system & oncology such as atherosclerosis and pulmonary hypertension.